Plenary Session 7











Attenzione: apre in una nuova finestra.

7 Monday, September 3, 2:30 – 4:15 pm
Barrett's esophagus
Endoscopic - Surgical treatments

Chairs:
M. Häfner (Vienna) – T. Ponchon (Lyons)
Discussant: J. Abrams (New York)
Secretary: A.K. Roorda (Morgantown)

  • What is the effect of endoscopic therapy on the BE genotype? N.S. Buttar (Rochester, MN)
  • Should patients with non-dysplastic Barrett esophagus be offered ablative therapy? P.D. Siersema (Utrecht)
  • Should patients with non-dysplastic Barrett esophagus  not be offered ablative therapy? Sharma (Gilbert)
  • Should patients with low-grade dysplastic BE offered ablative therapy? Should patients with low-grade dysplastic Barrett esophagus be offered ablative therapy? V. Sharma (Gilbert)
  • Should patients with low-grade dysplastic Barrett esophagus not be offered ablative therapy? S.J. Sontag (Chicago)
  • EMR or ablation or both for HGD? R.I. Rothstein (Lebanon)
  • How is cryotherapy comparing to radiofrequency for BE ablation? S.J. Sontag (Chicago)
  • How to endoscopically select ablation or EMR for dysplastic BE? J. Abrams (New York)
  • What is the value of trans-nasal endoscopy for BE screening? I.F. Herrmann (Munich)
  • Is ESD preferable to EMR for nodular lesions in Barrett’s esophagus? K.K. Wang (Rochester)
  • What is the current role of confocal endomicroscopy in Barrett's surveillance? T. Ponchon (Lyons)
  • How to approach proximal BE following esophago-gastric anastomosis? S. Szachnowicz (Sao Paulo)
  • Are GERD and BE more prevalent in gastroparesis? J.E. Richter (Tampa)
  • Esophagectomy or endoscopic resection for HGD and early cancer? B. Gayet (Paris)
  • What is the role of fundoplication in BE? A.K. Roorda (Morgantown)